Related Experiment Videos
[Clinical evaluation of panipenem/betamipron in pediatrics]
1Department of Pediatrics, Kagawa Children's Hospital, National Sanatrium.
Insights
Panipenem/betamipron (PAPM/BP) demonstrated high clinical efficacy, with a 95% success rate in treating pediatric bacterial infections. This antibiotic combination proved safe and effective across various infections, including pneumonia and meningitis.
Area of Science:
- Infectious Diseases
- Pediatric Medicine
- Pharmacology
Background:
- Bacterial infections pose a significant threat in pediatric populations.
- Effective and safe antimicrobial agents are crucial for treating pediatric infections.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of panipenem/betamipron (PAPM/BP) in pediatric patients.
- To assess PAPM/BP's effectiveness against a range of bacterial infections.
Main Methods:
- A total of 21 pediatric patients with various bacterial infections received intravenous PAPM/BP.
- Clinical responses and adverse events were systematically monitored.
- Panipenem concentrations in cerebrospinal fluid were measured in one case.
Main Results:
- PAPM/BP achieved an overall clinical efficacy rate of 95.0% (12 excellent, 7 good responses).
- The drug was effective in treating diverse infections like pneumonia, meningitis, and urinary tract infections.
- Minimal side effects were observed, with only one case of thrombocytosis noted.
Conclusions:
- Panipenem/betamipron (PAPM/BP) is an efficacious and safe therapeutic option for pediatric bacterial infections.
- The drug demonstrated good penetration into the cerebrospinal fluid.
- PAPM/BP represents a valuable addition to the pediatric infectious disease treatment armamentarium.
Abstract:
Studies were carried out on the clinical efficacy of panipenem/betamipron (PAPM/BP) against bacterial infections. The results are summarized as follows: 1. PAPM/BP were administered to total 21 patients (7 cases of pneumonia, 1 case of bronchitis, 3 cases of cellulitis, 2 cases of purulent lymphadenitis, 2 cases of otitis media, 1 case of purulent parotitis, 1 case of sinusitis, 1 case of mastoiditis, 2 cases of urinary tract infection and 1 case of purulent meningitis) by drip intravenous injection. 2. Clinical responses of PAPM/BP were excellent in 12 cases, good in 7, poor in 1 and unknown in 1 case. The overall efficacy rate was 95.0%. 3. Concentration of PAPM in cerebrospinal fluid after 1 hour drip intravenous administration in 1 case of purulent meningitis were 6.84 micrograms/ml at the acute stage and 3.28 micrograms/ml at the recovering stage. 4. Neither side effects nor abnormal laboratory findings were observed except 1 case of increase of thrombocytosis out of 19 cases. 5. From the results, PAPM/BP was determined to be an efficacious and safe drug for the therapy of pediatric infection.